158. Tuberous sclerosis Clinical trials / Disease details


Clinical trials : 108 Drugs : 67 - (DrugBank : 17) / Drug target genes : 35 - Drug target pathways : 118

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04285346
(ClinicalTrials.gov)
April 8, 202018/2/2020Adjunctive Ganaxolone Treatment (Part A) in TSC Followed by Long-term Treatment (Part B)A Phase 2 Open-label 12-Week Trial of Adjunctive Ganaxolone Treatment (Part A) in Tuberous Sclerosis Complex-related Epilepsy Followed by Long-term Treatment (Part B)Tuberous SclerosisDrug: GanaxoloneMarinus PharmaceuticalsNULLActive, not recruiting2 Years65 YearsAll24Phase 2United States